|Bid||0.00 x 1000|
|Ask||10.60 x 800|
|Day's Range||11.35 - 11.94|
|52 Week Range||10.15 - 121.98|
|Beta (5Y Monthly)||0.26|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 29, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||64.57|
The clinical-stage drugmaker's shares imploded last year in response to the failure of its lead Alzheimer's disease candidate atuzaginstat in a combined phase 2/3 study. Specifically, atuzaginstat reportedly missed both of its co-primary endpoints in the phase 2/3 Gain trial as a treatment for mild to moderate forms of Alzheimer's disease. Since announcing these disappointing trial results late last year, Cortexyme has said that it plans to trial the drug yet again.
Has Wall Street gotten ahead of itself? Depending on where one looks, it’s a fair enough question these days. But that certainly doesn’t include the market’s most-shorted stocks. Let’s take a look both off and on the price charts of three of last year’s heavily-shorted stocks at 52-week lows, which today are better-equipped to usher in a much happier 2022 for bullish investors. The start to the new year has been filled with highs and lows for index investors. After striking record breaking price
If you want to know who really controls Cortexyme, Inc. ( NASDAQ:CRTX ), then you'll have to look at the makeup of its...